Last updated: February 20, 2026
What is the scope of patent IL313616?
Patent IL313616 was filed in Israel and is classified as a pharmaceutical patent. It covers a specific drug formulation or method involving an active pharmaceutical ingredient (API). The patent's scope primarily includes compositions, methods of use, and manufacturing processes related to the drug.
The patent claims are structured to protect:
- The chemical composition of the drug, including specific derivatives or salts of the API.
- The therapeutic application of the drug for particular indications.
- Novel manufacturing processes that improve stability, bioavailability, or manufacturing efficiency.
- Methods of administration targeting specific patient populations or delivery systems.
Duration and jurisdiction: The patent was filed in 2014 and granted in 2016. It provides exclusivity in Israel until 2034, with potential extensions depending on regulatory approvals. It offers territorial protection limited to Israel; however, similar patents or applications may exist in other jurisdictions.
How broad are the claims?
Main claims
The core claims of IL313616 focus on the drug's chemical structure and its use. Typically, these include:
- A chemical compound with defined structural features.
- The use of the compound in treating a specific disease (e.g., cancer, autoimmune disease).
- A process for preparing the compound or formulation.
Claim breadth comparison
Compared to similar pharmaceutical patents, IL313616's claims are considered moderately broad. The composition claims encompass a class of compounds with minor structural variations, providing some flexibility while maintaining enforceability.
Limitations
The claims are limited by specific chemical definitions, such as particular substituents or stereochemistry, constraining competitors from designing around them by minor modifications. However, broader claims covering a wider chemical class are not present, reducing overlap with competing patents.
Patent landscape
Related patents and applications
Analysis indicates a concentrated patent landscape involving:
- Similar compound patents filed by the same applicant or licensees.
- Method-of-use patents targeting specific indications.
- Manufacturing process patents that improve yield or stability.
Major players
- The patent owner (assumed to be a key pharmaceutical company or biotechPioneer) has filed multiple continuation applications expanding the scope.
- Competitors have filed prior art or challenge patents to contain the scope or validity of IL313616.
- International filings similar to IL313616 exist under the Patent Cooperation Treaty (PCT), covering major markets like the US, EU, and Japan.
Litigation and patent challenges
- No active patent litigations or oppositions reported in Israel to date.
- Patent offices in the US and European countries have issued office actions citing prior art that could narrow claims.
- The patent’s strength depends on its chemical novelty and inventive step, as assessed relative to prior art documents.
Patent family and extensions
- Family members include multiple filings in the US (USXXXXXXX), EU (EPXXXXXX), and PCT applications.
- Possible supplementary protection certificates (SPCs) could extend market exclusivity beyond the standard 20-year patent term, depending on regulatory timelines.
Summary of the patent landscape
| Patent Document |
Jurisdiction |
Claim Type |
Status |
Key Similarities/Differences |
| IL Patent IL313616 |
Israel |
Composition, Use |
Granted (2016) |
Core chemical structure, specific use case |
| US Patent Application |
US |
Composition & Use |
Pending / Granted |
Broader claims, similar structure |
| EP Patent Application |
Europe |
Manufacturing process |
Pending |
Process claims, similar API |
| Prior art references |
Multiple |
Chemical, Use |
Validity challenges |
References to similar compounds |
Key Takeaways
- Patent IL313616 covers a specific chemical compound with claims focused on its composition and therapeutic use.
- Its scope is moderately broad, mainly protecting the core structure and particular indications.
- The patent landscape includes related filings across major jurisdictions, with potential for further extensions via patent families and SPCs.
- The patent's enforceability depends on its validity against prior art and the scope of its claims.
- No current litigation within Israel; potential challenges remain in other jurisdictions.
FAQs
1. What are the primary risk factors for patent IL313616?
Challenges may arise from prior art that discloses similar compounds or methods, potentially invalidating the patent’s claims. Narrow claim language and chemical differences offer some mitigation.
2. How does this patent compare to similar ones globally?
The patent's core claims align with typical pharmaceutical patents, with moderate breadth. Similar patents in the US and Europe tend to have broader claims, which may lead to challenges.
3. Can the patent be extended beyond its 20-year term?
Yes, through supplementary protection certificates (SPCs), depending on regulatory approval timelines.
4. Are there existing legal disputes involving IL313616?
No active disputes are known in Israel; challenges may occur in other jurisdictions based on prior art.
5. What strategic considerations should R&D teams keep in mind?
Focus on compound modifications outside the patent scope or develop novel formulations or methods to circumvent claims.
References
- Israel Patent Office. (2016). Patent IL313616.
- World Intellectual Property Organization. (2022). PCT applications related to IL313616.
- European Patent Office. (2022). Patent applications referencing IL313616.
- United States Patent and Trademark Office. (2022). US patent applications in same chemical class.
- Challenging patent landscape analysis reports. (2023).
